FI922850A0 - Menetelmä virusinaktivoidun verituotteen valmistamiseksi - Google Patents

Menetelmä virusinaktivoidun verituotteen valmistamiseksi

Info

Publication number
FI922850A0
FI922850A0 FI922850A FI922850A FI922850A0 FI 922850 A0 FI922850 A0 FI 922850A0 FI 922850 A FI922850 A FI 922850A FI 922850 A FI922850 A FI 922850A FI 922850 A0 FI922850 A0 FI 922850A0
Authority
FI
Finland
Prior art keywords
blood product
detergent
preparing
virus inactivated
inactivated blood
Prior art date
Application number
FI922850A
Other languages
English (en)
Swedish (sv)
Other versions
FI98491B (fi
FI98491C (fi
FI922850A (fi
Inventor
Johann Eibl
Friedrich Elsinger
Yendra Linnau
Gunther Woeber
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI922850A0 publication Critical patent/FI922850A0/fi
Publication of FI922850A publication Critical patent/FI922850A/fi
Priority to FI962613A priority Critical patent/FI105076B/fi
Publication of FI98491B publication Critical patent/FI98491B/fi
Application granted granted Critical
Publication of FI98491C publication Critical patent/FI98491C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Detergent Compositions (AREA)
FI922850A 1991-06-20 1992-06-18 Menetelmä virusinaktivoidun verituotteen valmistamiseksi FI98491C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI962613A FI105076B (fi) 1991-06-20 1996-06-24 Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0123791A AT402891B (de) 1991-06-20 1991-06-20 Verfahren zur herstellung eines inaktivierten blutproduktes
AT123791 1991-06-20

Publications (4)

Publication Number Publication Date
FI922850A0 true FI922850A0 (fi) 1992-06-18
FI922850A FI922850A (fi) 1992-12-21
FI98491B FI98491B (fi) 1997-03-27
FI98491C FI98491C (fi) 1997-07-10

Family

ID=3509572

Family Applications (2)

Application Number Title Priority Date Filing Date
FI922850A FI98491C (fi) 1991-06-20 1992-06-18 Menetelmä virusinaktivoidun verituotteen valmistamiseksi
FI962613A FI105076B (fi) 1991-06-20 1996-06-24 Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI962613A FI105076B (fi) 1991-06-20 1996-06-24 Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi

Country Status (14)

Country Link
US (2) US5614405A (fi)
EP (2) EP0519901B1 (fi)
JP (2) JP3011819B2 (fi)
AT (2) AT402891B (fi)
AU (1) AU648414B2 (fi)
CA (1) CA2071567C (fi)
CZ (2) CZ285115B6 (fi)
DE (1) DE59209735D1 (fi)
DK (1) DK0519901T3 (fi)
ES (1) ES2137178T3 (fi)
FI (2) FI98491C (fi)
HU (2) HU213470B (fi)
NO (2) NO305933B1 (fi)
SK (1) SK281412B6 (fi)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
EP0674531A1 (de) * 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
JPH08506498A (ja) 1993-02-09 1996-07-16 オクタファルマ・アクチエンゲセルシャフト 非脂質被覆ウイルスの失活方法
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
AT402788B (de) * 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
DE4342132C1 (de) 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
DE19617369A1 (de) * 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
US5837519A (en) * 1996-11-21 1998-11-17 Bayer Corporation Dry-heat viral inactivation under controlled moisture conditions
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT406120B (de) 1997-08-28 2000-02-25 Immuno Ag Gewebekleber
AT405739B (de) 1997-09-19 1999-11-25 Immuno Ag Verfahren zur reinigung von antithrombin iii
SI1151007T1 (sl) * 1999-02-12 2006-10-31 Baxter Ag Postopek za pripravo pripravka na osnovi fibrinogena in fibronektina in proteinski sestavki, ki jihlahko dobimo po tem postopku
AT410218B (de) 1999-08-20 2003-03-25 Baxter Ag Verfahren zur herstellung eines qualitätsgesicherten pools biologischer proben
FR2806910B1 (fr) * 2000-04-03 2003-01-24 Dolisos Lab Procede d'inactivation virale de solutions hydro-alcooliques
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
US7753945B2 (en) * 2003-01-17 2010-07-13 Gore Enterprise Holdings, Inc. Deployment system for an endoluminal device
EP1691727B1 (en) 2003-12-11 2011-07-06 Isto Technologies Inc. Particulate cartilage system
JP5292533B2 (ja) 2005-08-26 2013-09-18 ジンマー・インコーポレイテッド インプラントおよび関節疾患の治療、置換および治療方法
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
US20090012629A1 (en) * 2007-04-12 2009-01-08 Isto Technologies, Inc. Compositions and methods for tissue repair
WO2009021708A2 (en) 2007-08-13 2009-02-19 Baxter International Inc. Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
EP3590960B1 (en) 2012-02-29 2023-03-29 Takeda Pharmaceutical Company Limited Igg stimulated remyelination of peripheral nerves
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
EP4389157A2 (en) * 2013-11-15 2024-06-26 F. Hoffmann-La Roche AG Methods for viral inactivation using eco-friendly detergents

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5714653B2 (fi) * 1974-06-21 1982-03-25
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
US4250139A (en) * 1979-02-01 1981-02-10 Collagen Corporation Microwave sterilization of dry protein
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
EP0035204B2 (en) * 1980-03-05 1991-05-22 Miles Inc. Pasteurized therapeutically active protein compositions
EP0050061B2 (en) * 1980-10-06 1990-06-20 New York Blood Center, Inc. Method of reducing undesirable activities of biological and pharmaceutical products
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4480029A (en) * 1981-04-27 1984-10-30 Baxter Travenol Laboratories, Inc. Biological indicators and their use
JPS5874617A (ja) * 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
US4511556A (en) * 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
EP0124506B1 (de) * 1983-05-02 1988-08-17 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
DE3432083A1 (de) * 1984-08-31 1986-03-06 Behringwerke Ag, 3550 Marburg Pasteurisierte, isoagglutininfreie faktor viii-praeparation und verfahren zu ihrer herstellung
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
EP0413687A1 (en) * 1987-05-15 1991-02-27 Alan I. Rubinstein Sequential improved method for treatment of human blood-clotting factor products
IL86417A (en) * 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
DE3730533A1 (de) * 1987-09-11 1989-03-30 Biotest Pharma Gmbh Verfahren zur sterilisation von plasma oder plasmafraktionen
AT391809B (de) * 1988-01-12 1990-12-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutplasmaprodukten
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
ATE85220T1 (de) * 1988-05-27 1993-02-15 Centre Regional De Transfusion Verfahren zur herstellung eines hochreinen, virusfreien antihaemophiliefaktors mittels chromatographie.
AT397203B (de) * 1988-05-31 1994-02-25 Immuno Ag Gewebeklebstoff
AT390801B (de) * 1988-07-28 1990-07-10 Immuno Ag Verfahren zur herstellung von lys-plasminogen
US5156973A (en) * 1988-11-23 1992-10-20 Edward Shanbrom Antiviral blood sampling process and apparatus
DE3843126C3 (de) * 1988-12-22 1994-10-06 Octapharma Ag Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates
EP0378208B2 (en) * 1989-01-13 2003-01-15 Mitsubishi Pharma Corporation Production method for protein-containing composition
FR2644476A1 (fr) * 1989-03-15 1990-09-21 Sainte Agathe Nicolas De Procede de detection et/ou d'identification de micro-organismes vivants par vibrometrie
DE69027187T2 (de) * 1989-06-15 1996-10-31 Rorer Int Overseas Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen
IE73210B1 (en) * 1990-01-24 1997-05-07 Warner Lambert Co Process for the production of thrombin and high purity thrombin preparation thereby obtained
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
FR2679251B1 (fr) * 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
AT398079B (de) * 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
EP0587832B1 (en) * 1992-02-10 2001-07-11 Baxter International Inc. Method for testing blood units for viral contamination
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
FR2841484B1 (fr) * 2002-06-26 2004-09-10 Boucq De Beaudignies Ghisla Le Dispositif et procede de filtration de l'air et des gaz avec regeneration des particules captees

Also Published As

Publication number Publication date
HUT61477A (en) 1993-01-28
DE59209735D1 (de) 1999-09-23
CZ190292A3 (en) 1993-01-13
JP2000080042A (ja) 2000-03-21
JPH05186358A (ja) 1993-07-27
FI98491B (fi) 1997-03-27
JP3011819B2 (ja) 2000-02-21
US5614405A (en) 1997-03-25
FI105076B (fi) 2000-06-15
NO973996D0 (no) 1997-09-01
EP0519901A3 (en) 1993-05-19
CZ285115B6 (cs) 1999-05-12
NO922420D0 (no) 1992-06-19
NO922420L (no) 1992-12-21
FI98491C (fi) 1997-07-10
SK281412B6 (sk) 2001-03-12
AU648414B2 (en) 1994-04-21
FI962613A0 (fi) 1996-06-24
SK190292A3 (en) 1995-05-10
US5864016A (en) 1999-01-26
FI962613A (fi) 1996-06-24
FI922850A (fi) 1992-12-21
EP0519901A2 (de) 1992-12-23
EP0519901B1 (de) 1999-08-18
AU1830692A (en) 1992-12-24
JP3512163B2 (ja) 2004-03-29
AT402891B (de) 1997-09-25
CA2071567A1 (en) 1992-12-21
HU9201986D0 (en) 1992-09-28
DK0519901T3 (da) 2000-02-14
HU211545A9 (en) 1995-12-28
HU213470B (en) 1997-06-30
ATE183396T1 (de) 1999-09-15
CZ285552B6 (cs) 1999-09-15
CA2071567C (en) 2003-04-29
ATA123791A (de) 1997-02-15
ES2137178T3 (es) 1999-12-16
NO973996L (no) 1992-12-21
EP0882455A1 (de) 1998-12-09
NO305933B1 (no) 1999-08-23

Similar Documents

Publication Publication Date Title
FI98491B (fi) Menetelmä virusinaktivoidun verituotteen valmistamiseksi
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
ATE54828T1 (de) Behandlung von auf einer festen phase adsorbierten biologischen und pharmazeutischen produkten mit viren und pyrogenen inaktivierenden agenzien.
EP0247998A3 (en) Process for the inactivation of propagating filtrable pathogenic microbes
ATE148628T1 (de) 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
ATE298582T1 (de) Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
HUT61199A (en) Process for producing pharmaceutical compositions suitable for treating hyperlipidaemia and/or atherosclerosis
ES2006632A6 (es) Procedimiento de tratamiento termico de fibrinogeno.
AU568849B2 (en) Inactivation of viruses in virus containing protein samples
EP0571771A3 (en) Method of inactivation of viruses in proteinic preparations
DE50008992D1 (de) Verfahren zur Inaktivierung von Viren
DE3577801D1 (de) Verfahren zur herstellung von praeparationen auf basis von blutgerinnungsfaktoren.
FI872578A (fi) Menetelmä pastöroidun immunoglobuliinivalmisteen valmistamiseksi
DE69227899D1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
FI881123A0 (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
DE69210737T2 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
FI873602A0 (fi) Foerfarande foer inaktivering av vaermesensitiva, patogeniska, i blod existerande virus i igg-preparat.

Legal Events

Date Code Title Description
FG Patent granted

Owner name: IMMUNO AKTIENGESELLSCHAFT

BB Publication of examined application